The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -1.93 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M -1.11 — flag raised, worth a closer lookWatch
- Earnings quality 49/100 — worth a closer lookWatch
Where the revenue comes from
Fiscal 2025, as Kura Oncology, Inc. reports it. History and quarterly detail are in the app.
- License And Collaboration Revenue$65.3M
- Collaboration Revenue$65.3M
- Product$2.1M
Leadership changes
From Kura Oncology, Inc.'s own filings, the day they're filed.
- Stephen Dale · Chief Medical Officer · departureeff. 2025-01-02
- Michael J. Vasconcelles · director · appointment
Latest filings
- 8-K · Company announcement2026-06-04
- 8-K · Company announcement2026-05-12
- 10-Q · Quarterly report2026-05-12
- DEF 14A · Annual proxy (pay & governance)2026-04-10
- 10-K · Annual report2026-03-05
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about Kura Oncology, Inc., every answer cited🔒
- The Intelligence Brief — added when Kura Oncology, Inc.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.